Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
2015 StandoutNobel
Transferred WT1-Reactive CD8 + T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
2013
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
2010
Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance
2012
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
2013 StandoutNobel
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Jinx , an MCMV susceptibility phenotype caused by disruption of Unc13d : a mouse model of type 3 familial hemophagocytic lymphohistiocytosis
2007 StandoutNobel
Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent
2015
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
2014
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
2006 StandoutScience
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
2012
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
2006
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
2015
Combinatorial Cancer Immunotherapy
2006
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
2013 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Therapeutic cancer vaccines: are we there yet?
2010
Endogenous T-Cell Therapy
2015
Adoptive T cell therapy for cancer in the clinic
2007
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
2013
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
2013
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma
2007
Imaging in the era of molecular oncology
2008 StandoutNature
Dendritic Cells
2010
Cancer immunotherapy: breaking the barriers to harvest the crop
2004 StandoutNobel
Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
2013
Dendritic cells: versatile controllers of the immune system
2007 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cancer immunotherapy via dendritic cells
2012 Standout
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
2008
Adoptive immunotherapy for cancer: building on success
2006
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self
2005 StandoutNobel
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
2008
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Bystander elimination of antigen loss variants in established tumors
2004
Engineered T cells: the promise and challenges of cancer immunotherapy
2016
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
2008
Taming cancer by inducing immunity via dendritic cells
2007
Principles of adoptive T cell cancer therapy
2007
Immunity, Inflammation, and Cancer
2010 Standout
Molecules and mechanisms of the graft-versus-leukaemia effect
2004
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
2012 Nature
Emerging Biological Principles of Metastasis
2017 Standout
Antigens for cancer immunotherapy
2008
Hematopoietic Stem-Cell Transplantation
2006 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
EMT: 2016
2016 Standout
Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy
2009
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
Cancer immunotherapy comes of age
2011 StandoutNature
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells
2003
TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis
2008
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
2013
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Cancer Immunology
2008
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
2005
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
2004
Cancer-related inflammation
2008 StandoutNature
Adoptive-cell-transfer therapy for the treatment of patients with cancer
2003
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
The Immunobiology of Cancer Immunosurveillance and Immunoediting
2004 Standout
Adoptive Immunotherapy for Cancer or Viruses
2014
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
Recent Developments in Cancer Vaccines
2011
IL-21–mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes
2007
High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens
2003
Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
2007 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells To Program Cytotoxic Th1 Differentiation
2011
Cancer Immunotherapy Comes of Age
2011
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy
2007
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Cancer Immunotherapy: A Treatment for the Masses
2004 Science
Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells
2005 Nobel
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
2008 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
The Stoichiometric Production of IL-2 and IFN-γ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans
2012
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
2008
Chimeric Antigen Receptor Therapy
2018 Standout
Does the Immune System See Tumors as Foreign or Self?
2003
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
CD4 cells can be more efficient at tumor rejection than CD8 cells
2007
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response
2005
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic Cells
2004
Neoantigens in cancer immunotherapy
2015 StandoutScience
Immune Therapy for Cancer
2008
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells
2005
Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response
2009
Works of D. Byrd being referenced
Abstract S2-1: The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial
2012
Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
2002